Grupo de Neuroblastoma SEHOP, Unidad de Oncología Pediátrica, Hospital Universitario La Fe, Valencia, Spain.
Clin Transl Oncol. 2010 Dec;12(12):788-93. doi: 10.1007/s12094-010-0600-y.
Anticancer monoclonal antibodies (mAbs) targeting specific antigens on the tumour surface are increasingly being applied in cancer treatment. Potential advantages include long half-life, low toxicity, high affinity and specificity. In order to develop novel immune therapies for high-risk cancers, finding tumour targets that are not widely shared by normal cells is a goal. GD2-disialoganglioside is one of them. It is expressed on the surface of a variety of tumours with no curative therapies for patients with advanced disease. In childhood, neuroblastoma is the most common GD2-expressing tumour. Because of this tumour-selective expression, it is an attractive target for tumour-specific therapies such as antibody therapy. Over the last two decades, several anti-GD2 antibodies have been developed. To reduce both toxicity and development of human anti-mouse antibodies (HAMA), research efforts have primarily focused on exploring anti-GD2 antibodies that substitute mouse components by human ones. This review will examine antibodies currently undergoing clinical testing as well as the most recent advances to improve antibody therapy for patients with high-risk neuroblastoma.
用于治疗癌症的抗癌单克隆抗体（mAbs）越来越多地针对肿瘤表面的特定抗原。其潜在优势包括半衰期长、毒性低、亲和力和特异性高。为了开发高危癌症的新型免疫疗法，寻找肿瘤靶点是一个目标，这些靶点不应广泛存在于正常细胞中。GD2-二唾液酸神经节苷脂就是其中之一。它存在于多种肿瘤的表面，而晚期疾病患者尚无治愈疗法。在儿童中，神经母细胞瘤是最常见的 GD2 表达肿瘤。由于这种肿瘤选择性表达，它是肿瘤特异性治疗（如抗体治疗）的一个有吸引力的靶点。在过去的二十年中，已经开发了几种抗 GD2 抗体。为了降低毒性和人抗鼠抗体（HAMA）的产生，研究工作主要集中在探索通过替代鼠成分来减少毒性和产生人抗鼠抗体（HAMA）的抗 GD2 抗体。这篇综述将检查目前正在进行临床试验的抗体以及最新进展，以改善高危神经母细胞瘤患者的抗体治疗。
